Ridgeback Capital Management LLC has recently announced that it has increased stake in Affimed N.V. (NASDAQ:AFMD) by 66.83%. After grabbing 12.88 million shares, the institutional investor is now in possession of 5.16 million shares of the Healthcare Company. The new investment brought the stake of investor firm to 8.63% having worth around $5.8 million. Moreover, Verition Fund Management LLC increased its share by 0.31 million to have a control over 1.09 million shares. And Morgan Stanley & Co. LLC raised its holdings to 0.32 million shares by acquiring 1.03 million shares or 0.69% of the stake.
Affimed N.V. (AFMD) concluded trading on 12/21/23 at a closing price of $0.46, with 2.64 million shares of worth about $1.22 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -30.03% during that period and on Thursday the price saw a gain of about 20.37%. Currently the company’s common shares owned by public are about 149.34M shares, out of which, 128.33M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
A deeper look into what the analysts at Wall Street are thinking about the price target of this stock provides us with the following: 7 analysts are covering the AFMD stock and their offered price forecasts bring an average price target of $5.03. Over the next 12 months, analysts forecasted that the stock’s price could jump as high as $12.07 and could fall to a lowest price of $0.93. The stock’s current price level is 91.54% above of average price target set by the analysts, while a rise to estimated low would result in gain of 50.54% for the stock. However, touching the estimated high of $12.07 would mean a gain of 96.19% for the stock.
Pictet – Biotech, Granahan Funds Plc – US SMID Sele, and iShares Biotechnology ETF are the top 3 mutual funds which are holding stakes in Affimed N.V. Pictet – Biotech is currently holding 2.55 million shares of worth totaling $1.15 million. The company recently came buying 0.0 shares which brought its stake up to 1.71% of the company’s outstanding shares. Granahan Funds Plc – US SMID Sele bought 0.32 million shares, after which its hold over company’s outstanding shares expand to 0.89%, leaving 1.32 million shares with the mutual fund that have a worth of about $0.6 million. iShares Biotechnology ETF, after selling 0.85 million shares, have now control over 0.57% of the stake in the company. It holds 4722.0 shares of worth $0.38 million.
Affimed N.V. (NASDAQ: AFMD) started trading at $0.37, below -$0.01 from concluding price of the previous day. However, the stock later moved at a day high price of 0.4765, or with a gain of 20.37%. Stock saw a price change of 13.30% in past 5 days and over the past one month there was a price change of -6.57%. Year-to-date (YTD), AFMD shares are showing a performance of -63.31% which decreased to -60.43% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.22 but also hit the highest price of $1.35 during that period. The average intraday trading volume for Affimed N.V. shares is 846.38K. The stock is currently trading 5.88% above its 20-day simple moving average (SMA20), while that difference is up 14.61% for SMA50 and it goes to -24.96% lower than SMA200.
Ridgeback Capital Management LLC acquired 12.88 million shares of Affimed N.V. having value of about $5.8 million. Data submitted at the U.S SEC by Ridgeback Capital Management LLC revealed that the firm now holds 5.16 million shares in the company valued at close to $2373831.84, or have control over 66.83% stake in the company. Affimed N.V. (NASDAQ: AFMD) currently have 149.34M outstanding shares and institutions hold larger chunk of about 31.65% of that. Holding of mutual funds in the company is about 25.59% while other institutional holders and individual stake holders have control over 6.46% and — of the stake respectively.
The stock has a current market capitalization of $67.95M and its 3Y-monthly beta is at 1.98. It has posted earnings per share of -$0.85 in the same period. It has Quick Ratio of 3.67 while making debt-to-equity ratio of 0.28. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AFMD, volatility over the week remained 13.09% while standing at 12.98% over the month.
Analysts are in expectations that Affimed N.V. (AFMD) stock would likely to be making an EPS of -$0.18 in the current quarter, while forecast for next quarter EPS is -$0.17 and it is -$0.68 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.21 which is -$0.15 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.24 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -20.82% while it is estimated to increase by 16.10% in next year.
Analysts at 7 brokerage firms have issued recommendations for the Affimed N.V. (AFMD)’s stock and average of those rates the stock at a “Strong Buy” and assign it a score of 1.29. Out of those 7 Wall Street analysts, 6 recommended a “Buy” rating, while 1 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on December 12, 2022 offering a Buy rating for the stock and assigned a target price of $6 to it.
